S&P Futures
3,763.50 -57.75 (-1.51%) Dow Futures
30,633.00 -366.00 (-1.18%) Nasdaq Futures
11,465.00 -226.00 (-1.93%) Russell 2000 Futures
1,694.00 -27.40 (-1.59%) Crude Oil
110.05 +0.27 (+0.25%) Gold
1,815.00 -2.50 (-0.14%)
Atara Biotherapeutics, Inc. (ATRA)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 6.55 |
| Open | 6.54 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's Range | 6.50 - 7.63 |
| 52 Week Range | 4.61 - 20.04 |
| Volume | |
| Avg. Volume | 1,133,933 |
| Market Cap | 708.015M |
| Beta (5Y Monthly) | 1.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.64 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.86 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ATRA
Related Research
- Atara Biotherapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 06/16/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
- Simply Wall St.
Atara Biotherapeutics (NASDAQ:ATRA) shareholders are up 17% this past week, but still in the red over the last three years
This week we saw the Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) share price climb by 17%. But only the myopic could...
- Business Wire
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress
SOUTH SAN FRANCISCO, Calif., June 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced EMA regulatory progress and tabelecleucel (tab-cel®) clinical outcomes. Data is reported from the multicenter Expanded Access Program (EAP) study in Europe for patients with relapsed or refractory (r/r) Epstein-Barr virus-dr
- Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 03, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 126,928 restricted stock units of Atara’s common stock to four newly hired employees and stock options to purchase an aggregate of 186,378 shares of Atara’s common stock to three such newly hired
